AI Score

Unlock

Avalo Therapeutics Inc. (AVTX)

AI Score

Unlock

6.69

-0.62 (-8.48%)

At close: Mar 03, 2025, 3:59 PM

6.70

0.15%

After-hours: Mar 03, 2025, 04:00 PM EST

No 1D chart data available

Bid	6.42
Market Cap	70M
Revenue (ttm)	1.06M
Net Income (ttm)	-10.24M
EPS (ttm)	94.42
PE Ratio (ttm)	0.07
Forward PE	-1.71
Analyst	Buy

Ask	6.98
Volume	24,183
Avg. Volume (20D)	88,887
Open	7.31
Previous Close	7.31
Day's Range	6.57 - 7.31
52-Week Range	4.35 - 34.46
Beta	0.93

About AVTX

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 14, 2015

Employees 19

Stock Exchange NASDAQ

Ticker Symbol AVTX

Website https://www.avalotx.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 460.54% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

6 months ago

+8.88%

Avalo Therapeutics shares are trading higher after... Unlock content with Pro Subscription

10 months ago

+4.59%

Avalo Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $35 price target.

News

7 months ago · investorplace.com

The 3 Best Personalized Nutrition Stocks to Buy Now

It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine...

9 months ago · zacks.com

Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?

Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.

11 months ago · zacks.com

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

11 months ago · invezz.com

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.

11 months ago · investorplace.com

Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?

Avalo Therapeutics (NASDAQ: AVTX ) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big update w...

11 months ago · zacks.com

Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know

Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.